Literature DB >> 27867566

Effectiveness of temporary positive expiratory pressure (T-PEP) at home and at hospital in patients with severe chronic obstructive pulmonary disease.

Valentina Mascardi1, Bruna Grecchi2, Cornelius Barlascini3, Paolo Banfi4, Antonello Nicolini1.   

Abstract

BACKGROUND: Temporary positive airway pressure (T-PEP) is a tool recently introduced in the treatment of chronic obstructive pulmonary disease (COPD) or bronchiectasis. It demonstrated encouraging results also in severe COPD patients. The aim of this study is verify if adding T-PEP to best bronchodilator therapy both in clinic and home administering could reduce disease exacerbations and improve lung function in patients with severe COPD.
METHODS: A total of 142 patients with severe COPD (FEV1 <50%) were enrolled; 120 were randomized in three groups: a group treated with T-PEP at home, a group with T-PEP at hospital and a group with medical therapy only (control group). Number of acute exacerbations COPD (AECOPD) after 1 month and 3 months were the primary outcomes. Secondary outcomes were changes in respiratory function parameters (FVC, FEV1, TLC, RV), arterial blood gases, dyspnea and health status assessment scales (Modified Medical Research Council (MMRC), Breathlessness, Cough and Sputum scale (BCSS) and COPD Assessment Test (CAT). The time of daily use of the T-PEP was registered as well as its acceptance using a Likert scale.
RESULTS: Ninety-nine patients completed the study. Both the groups who used T-PEP showed a statistical lower number of AECOPD after 1 month and 3 months (P<0.01). Some respiratory functional parameters improved in the two groups treated with T-PEP (FVC, FEV1, RV) (P<0.02) and dyspnea and health status assessment scales (MMRC, BCSS, CAT) (P<0.04; P<0.01; P<0.009). The time of daily using was similar in the two T-PEP groups. Patients treated at home showed a greater acceptance than those treated at hospital (Likert scale 4.7 vs. 5.9) (P<0.01).
CONCLUSIONS: Patients treated with T-PEP showed a lower number of AECOPD. T-PEP improves functional respiratory parameters and improves dyspnea and health status assessment scales. No adherence difference in hospital and home treatment was found. Patients preferred home treatment.

Entities:  

Keywords:  Severe chronic obstructive pulmonary disease; home administering; hospital administering; temporary expiratory pressure (T-PEP)

Year:  2016        PMID: 27867566      PMCID: PMC5107462          DOI: 10.21037/jtd.2016.10.69

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  21 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

2.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

3.  Comparison of intermittent positive pressure breathing and temporary positive expiratory pressure in patients with severe chronic obstructive pulmonary disease.

Authors:  Antonello Nicolini; Elena Mollar; Bruna Grecchi; Norma Landucci
Journal:  Arch Bronconeumol       Date:  2013-12-08       Impact factor: 4.872

Review 4.  Mucoactive agents for airway mucus hypersecretory diseases.

Authors:  Duncan F Rogers
Journal:  Respir Care       Date:  2007-09       Impact factor: 2.258

5.  The breathlessness, cough, and sputum scale: the development of empirically based guidelines for interpretation.

Authors:  Nancy Kline Leidy; Stephen I Rennard; Jordana Schmier; M Kathryn C Jones; Mitch Goldman
Journal:  Chest       Date:  2003-12       Impact factor: 9.410

6.  Efficacy of temporary positive expiratory pressure (TPEP) in patients with lung diseases and chronic mucus hypersecretion. The UNIKO® project: a multicentre randomized controlled trial.

Authors:  Elena Venturelli; Ernesto Crisafulli; Assunta DeBiase; Daniela Righi; Daniele Berrighi; Pier Paolo Cavicchioli; Guido Vagheggini; Francesco Dabrosca; Bruno Balbi; Mara Paneroni; Luca Bianchi; Michele Vitacca; Vittoria Galimberti; Michele Zaurino; Giorgio Schiavoni; Andrea Iattoni; Nicolino Ambrosino; Enrico M Clini
Journal:  Clin Rehabil       Date:  2012-09-11       Impact factor: 3.477

7.  Physiologic evidence for the efficacy of positive expiratory pressure as an airway clearance technique in patients with cystic fibrosis.

Authors:  Joan C Darbee; Patricia J Ohtake; Brydon J B Grant; Frank J Cerny
Journal:  Phys Ther       Date:  2004-06

Review 8.  A review of the most common patient-reported outcomes in COPD--revisiting current knowledge and estimating future challenges.

Authors:  Mario Cazzola; Nicola Alexander Hanania; William MacNee; Katja Rüdell; Claire Hackford; Nihad Tamimi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-04-07

9.  Lung flute improves symptoms and health status in COPD with chronic bronchitis: A 26 week randomized controlled trial.

Authors:  Sanjay Sethi; Jingjing Yin; Pamela K Anderson
Journal:  Clin Transl Med       Date:  2014-09-23

10.  Validity and Reliability of CAT and Dyspnea-12 in Bronchiectasis and Tuberculous Destroyed Lung.

Authors:  Bo Young Lee; Seohyun Lee; Jae Seung Lee; Jin Woo Song; Sang-Do Lee; Seung Hun Jang; Ki-Suck Jung; Yong Il Hwang; Yeon-Mok Oh
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-06-29
View more
  2 in total

1.  Safety and effectiveness of the high-frequency chest wall oscillation vs intrapulmonary percussive ventilation in patients with severe COPD.

Authors:  Antonello Nicolini; Bruna Grecchi; Maura Ferrari-Bravo; Cornelius Barlascini
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-02-16

Review 2.  Airway Clearance Techniques: The Right Choice for the Right Patient.

Authors:  Stefano Belli; Ilaria Prince; Gloria Savio; Elena Paracchini; Davide Cattaneo; Manuela Bianchi; Francesca Masocco; Maria Teresa Bellanti; Bruno Balbi
Journal:  Front Med (Lausanne)       Date:  2021-02-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.